ERBB2 and neoplasm: Moreover, patients with HER2 IHC 2+ tumours and high HER2 gene amplification level had lower pCR rate when compared with all HER2 IHC 3+ tumours regardless of their gene amplification levels (17% vs 57%, P = 0.001).